Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 30;11(1):3801.
doi: 10.1038/s41467-020-17670-y.

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert  1
Affiliations

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert. Nat Commun. .

Abstract

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.

PubMed Disclaimer

Conflict of interest statement

C.R. is occasional consultant for Roche, BMS, MSD, Merck, Sanofi, Pierre Fabre, Biothera, CureVac, Novartis.

References

    1. Xin Y J, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat. Rev. Drug Discov. 2019;18:899–900. doi: 10.1038/d41573-019-00167-9. - DOI - PubMed
    1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004;10:909–915. doi: 10.1038/nm1100. - DOI - PMC - PubMed
    1. Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562:20–21. doi: 10.1038/d41586-018-06751-0. - DOI - PubMed
    1. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093. - DOI - PubMed
    1. Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 10.1056/NEJMoa1910836 (2019). - PubMed

MeSH terms